



wings4innovation GmbH (w4i) was founded

- as affiliate of KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I), a new European financing vehicle for early-stage drug discovery projects with focus in Austria and Germany
- to facilitate translation of promising results from Austrian basic research organisations in life sciences into professional drug discovery projects and their commercialisation
- with access to funds of KHAN-I
- open to all research organisations in Austria

Main tasks of w4i

- Scouting in collaboration with TTOs for and filtering and evaluation of innovative project ideas/proposals
- Presentation of elaborated cases to the w4i Advisory Board (AB)
- After AB approval, application for investment by KHAN-I
- Coordination of work packages of funded projects on behalf of KHAN-I
- Drug discovery consulting

Requirements for funding

- Findings & hypotheses (not necessarily IP!) that may lead to an **innovative therapy** (small molecules and biologics) with high **unmet medical need**
- In-depth scientific know-how at Principal Investigator (PI)
- **Close collaboration** between w4i and PI
- **Active in-kind contribution** by PI
- Technical feasibility, chance for commercialisation
- Approval by the w4i Advisory Board and the KHAN-I Investment Advisory Committee

Organisational aspects

- submission of project proposals to info@w4i.org
guide available at www.w4i.org
- managing director: Peter Nussbaumer
translational guides: Andreas Billich
Thomas Kirmeier
- contact: info@w4i.org